Theralase Technologies Inc. V.TLT

Only 12 Evaluable Patients at 450 days 67% CR !!!!!!

[Eoganacht]

??????????

	90 days	180 days	270 days	360 days	450 days
CR	54%	62%	56%	43%	67%
IR	12%	22%	22%	10%	17%
TR	65%	84%	78%	52%	83%
Evaluable patients	52	37	27	21	12

[Alamir1111]

 I know nr still confusing but I like 86 percentages  We might be onto something  special

[Jaro1977]

The ASCO poster stated 29 evaluable patients. Why do you think it's only 12 now?

[DJDawg]

That is so strange. I feel like the AUA poster will be needed to clean up the data presentation. 12 evaluable makes no sense when they said 29 evaluable before.

[Eoganacht]

I'm not sure yet, but I think they may have changed the definition of "evaluable" I think it now means the patients that could be evaluated at any point in time. So at 450 days all of the no response patients were dropped except the 2 that were actually evaluated no reponse at 450 days. I still need to dig a some more.

[enriquesuave]

In the Swimmers plot, it shows all 56 patients, but only 12 reached 450 days. I believe they are excluding (maybe 16 patients that 12+1 +3). Only counting patients which are not excluded at 450 days or those who got 2 fully optimized patients.?

[TimboBaggins]

If only the company could release news that was coherent and straight forward. We're always left trying to make sense of this garbage. Why can't they explain why the numbers dropped???? Yeah F us I guess. 

[Jaro1977]

Reading the MD&A it states that 12 patients have been CR for 12 months post initial CR.  The other 17 patients from the ASCO poster are not yet CR over the course of 12 months.  I think it's very good news.

[Alamir1111]

Playing games to  confuse  compettion???? Sure works on us .

[enriquesuave]

Maybe at 450 days they are only counting PH2 patients which got 2 optimized treatments ( excluding initial 12+1 who died, plus 3 from PH1 which were previously included. That's 28 patients minus 16 excluded now=12) This would make more sense for the FDA and market to truly evaluate the potential of this tech with 2 proper optimized treatments as per study protocol.  That's 67% CR plus

[enriquesuave]

Perhaps I could be right, but only making a good guess. We shall find out after AUAperhaps

[Rumpl3StiltSkin]

I think I felt it move.... 

[riverrrow]

So is the bottom line that TLT now has enough patients reaching 450 days that were treated correctly with the right dose for the results to be statistically significant? TLT can now drop those patients that were under dosed and Phase 1 patients that didn't really meet the trial protocol. While the 67% seems astronomical, on a science level it makes sense to me. Also, don't forget the 2 out

[Rumpl3StiltSkin]

Yep River, Seems that way to me. We get 1st qtr data end of May, I think. Then the AGM happens end of June. I wonder how close TLT will be to continuing Phase 2 towards BTD and AA at those points?

[Alamir1111]

So rr .Should we tickle those 8  cent warrants for the fun of it

[O12009]

So they haven't applied to the FDA? I was trying to do the math to figure out 12 patients. If you take away the 3 from phase1 , the 12 under treated and the one who died, from 29 that will leave 13? So I'm guessing that is not it, unless there was another under treated.

[Jaro1977]

The Company is currently working with both a biostatistics and regulatory organization to compile a clinical data report for submission to the FDA in support of the grant of a BTD approval. From MD&A

[2b7f6fab]

There's been too much vetching on this board the past couple of months. Again the belly aching begins because some can't fathom the response numbers.. Y can't people relax and be more zen like? Consider the TR percentages as ball park figures. Don't get all caught up in the minutia. CAN YOU SAY HOLY EXCREMENT BATMAN, DID YOU SEE THOSE TR PERCENTAGES?